{"url_path":"/sec/celc/8-k/2026-06-02/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1603454/0001493152-26-026761-index.html","accession_number":"0001493152-26-026761","cik":"0001603454","ticker":"CELC","issuer_name":"Celcuity Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1603454/0001493152-26-026761-index.html","primary_entity_key":"0001603454","primary_entity_name":"Celcuity Inc."},"word_count":136,"has_tables":true,"body_markdown":"**Item\n7.01**\n**Regulation\nFD Disclosure.**\n\n \n\nOn\nJune 2, 2026, Celcuity Inc. (the “Company”) issued a press release announcing detailed efficacy and safety results from its\n*PIK3CA* mutant-type (“MT”) cohort of its Phase 3 VIKTORIA-1 clinical trial. A copy of the press release is furnished\nas Exhibit 99.1 to this report and is incorporated herein by reference.\n\n \n\nThe\ninformation in this Item 7.01, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for\npurposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the\nliabilities of that Section. The information in this Item 7.01 shall not be incorporated into any filing pursuant to the Securities Act\nof 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing."}